What is the renal‑adjusted colistin dose for a 65‑kg patient with Klebsiella urosepsis and acute kidney injury?

Colistin Dosing for Klebsiella Urosepsis with AKI (65 kg patient)

For a 65 kg patient with Klebsiella urosepsis and acute kidney injury, administer a loading dose of 9 MU (million units) of colistimethate sodium (CMS) followed by maintenance doses calculated using the formula: 2.5 mg × (1.5 × CrCl + 30) twice daily, where the specific dose depends on the patient's creatinine clearance at the time of dosing. 1

Loading Dose Strategy

The loading dose remains 9 MU regardless of renal function because colistin has a large volume of distribution and the loading dose is needed to rapidly achieve therapeutic plasma concentrations 1. This is critical in sepsis where early adequate antimicrobial levels directly impact mortality.

• Do not reduce or omit the loading dose even in severe AKI—this is a common pitfall that leads to subtherapeutic levels during the critical first 24-48 hours
• Administer as a slow IV injection over 3-5 minutes 2

Maintenance Dosing Based on Creatinine Clearance

After the loading dose, maintenance dosing must be adjusted based on the patient's current renal function using the formula from the 2022 guidelines: 4.5 MU × [2.5 mg × (1.5 × CrCl + 30)] twice daily 1

Specific Dosing by AKI Severity:

For your 65 kg patient, calculate the creatinine clearance and apply:

• CrCl ≥80 mL/min: 4.5 MU twice daily (standard dose)
• CrCl 50-79 mL/min (mild AKI): 2.5-3.8 mg/kg divided into 2 doses = approximately 3.4-4.1 MU twice daily 2
• CrCl 30-49 mL/min (moderate AKI): 2.5 mg/kg once daily or divided into 2 doses = approximately 2.7 MU twice daily or 5.4 MU once daily 2
• CrCl 10-29 mL/min (severe AKI): 1.5 mg/kg every 36 hours = approximately 1.6 MU every 36 hours 2

Critical Monitoring Requirements

Monitor serum creatinine at baseline, then on days 4,7,11,14, and 21 (or at therapy discontinuation if earlier) 3. This is non-negotiable given that:

• AKI occurs in 30-50% of colistin-treated patients 3, 4
• Risk estimates for AKI are 30.6% at 7 days and 58.8% at 14 days 3
• The median time to AKI onset is 5 days 5

Dose Adjustment During Treatment

Recalculate and adjust the maintenance dose every 2-3 days based on evolving renal function, as AKI can worsen or improve during therapy. The guidelines explicitly state there is "no current consensus regarding frequency of dose adjustment" in AKI 1, but clinical prudence dictates frequent reassessment.

Important Caveats and Pitfalls

Combination Therapy Consideration

While the evidence for combination therapy is controversial 1, strongly consider adding a second agent (carbapenem, aminoglycoside, or tigecycline) based on susceptibility testing, particularly in severe sepsis. The guidelines note that combination therapy may reduce mortality even when the second agent lacks in vitro activity 1.

Nephrotoxicity Risk Factors

Your patient has multiple risk factors for colistin-induced AKI:

• Pre-existing AKI increases risk 3
• Doses >5 mg/kg/day independently predict AKI within 7 days 4
• Concomitant nephrotoxins (especially vancomycin) significantly increase risk 4

Avoid or minimize concomitant vancomycin, aminoglycosides, NSAIDs, and contrast agents whenever possible 4.

Urinary Tract Source Considerations

For urosepsis specifically, colistin achieves excellent urinary concentrations. Recent data shows favorable clinical outcomes (87.3% clinical success) with lower AKI rates (14.7%) in UTI patients compared to other infection sources 6. However, do not reduce systemic dosing for urinary infections—the sepsis component requires full therapeutic plasma levels.

Duration of Therapy

Limit colistin duration to the minimum effective period (typically 7-14 days for urosepsis) to minimize cumulative nephrotoxicity risk 4. Seven percent of patients require renal replacement therapy at a median of 5 days after colistin initiation 4.

Practical Algorithm Summary

1. Day 1: Give 9 MU loading dose regardless of renal function
2. Calculate CrCl: Use Cockcroft-Gault with actual body weight (65 kg)
3. Start maintenance: Use formula or table above based on CrCl
4. Day 4: Recheck creatinine, recalculate CrCl, adjust dose
5. Day 7: Recheck creatinine, recalculate CrCl, adjust dose
6. Continue: Monitor every 3-4 days until completion

The evidence strongly supports this structured approach prioritizing both efficacy (adequate loading dose) and safety (renal-adjusted maintenance dosing with frequent monitoring) 1, 2.